Wednesday, Sep 23, 2020 | Last Update : 11:10 PM IST

183rd Day Of Lockdown

Maharashtra122438091634833015 Andhra Pradesh6317495518215410 Tamil Nadu5473374919718871 Karnataka5268764233778145 Uttar Pradesh3588932895945135 Delhi2492592133045014 West Bengal2283021989834421 Odisha184122149379763 Telangana1726081419301042 Bihar169856155824870 Assam159320129130578 Kerala13863398720554 Gujarat1247671051913337 Rajasthan116881972841352 Haryana113075908841177 Madhya Pradesh108167836182007 Punjab99930754092860 Chhatisgarh8618347653680 Jharkhand7267358543626 Jammu and Kashmir65026421151024 Uttarakhand4177729000501 Goa2875322726360 Puducherry2319118065467 Tripura2227215441245 Himachal Pradesh124387836125 Chandigarh102987411123 Manipur9010683859 Arunachal Pradesh7385540813 Nagaland5544445110 Meghalaya4733252838 Sikkim2447190529 Mizoram158510120
  Business   Companies  23 Jun 2020  Gilead Sciences to start trials of inhaled version of remdesivir

Gilead Sciences to start trials of inhaled version of remdesivir

ANI
Published : Jun 23, 2020, 3:47 pm IST
Updated : Jun 23, 2020, 3:47 pm IST

The FDA granted remdesivir an emergency use authorisation for the treatment of hospitalised patients with severe Covid-19

  Gilead Sciences will soon start clinical trials for inhaled formulation of its anti-viral drug remdesivir. (ANI Photo)
  Gilead Sciences will soon start clinical trials for inhaled formulation of its anti-viral drug remdesivir. (ANI Photo)

California: US-based biopharmaceutical major Gilead Sciences will soon start clinical trials for inhaled formulation of its anti-viral drug remdesivir used for the treatment of Covid-19.

"After receiving the green light from the Food and Drug Administration to move forward, Gilead is about to start trials of an inhaled version of remdesivir," said Chairman and CEO Daniel O'Day.

 

"We will screen healthy volunteers for phase one trials this week and hope to begin studies in patients with Covid-19 in August. If the trials are successful, this could represent important progress," he said in a message posted on the company's website.

Remdesivir, the investigational anti-viral medicine, is currently given to patients intravenously through daily infusions in the hospital. An inhaled formulation will be given through a nebuliser which could potentially allow for easier administration outside the hospital at earlier stages of disease.

"That could have significant implications in helping to stem the tide of the pandemic," said O'Day. "As part of our next wave of clinical development, we will study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups."

 

O'Day said as part of the aim to benefit as many patients as possible, Gilead Sciences is focused on ensuring sufficient supplies of remdesivir and enabling access.

"We now expect to have more than two million remdesivir treatment courses manufactured by the end of the year and many millions more by 2021. Our scientists will stay focused on optimising the manufacturing process, and we will continue to collaborate globally to ensure sufficient worldwide supply."

Remdesivir is an anti-viral product that is being studied in multiple ongoing international clinical trials. It has not been approved by the US FDA for any use.

In the United States, the FDA granted remdesivir an emergency use authorisation for the treatment of hospitalised patients with severe Covid-19. This authorisation is temporary and may be revoked, and does not take the place of the formal new drug application submission, review and approval process.

 

Tags: us, biopharmaceutical, gilead sciences, inhaled formulation, anti-viral drug, remdesivir, covid-19
Location: United States, California, Fairfield